Postinfectious irritable bowel syndrome

Clinical Infectious Diseases

Volumn 46, Issue 4, 2008, Pages 594-599

  DuPont, Andrew W ^a,b  

^a UNIVERSITY OF TEXAS MEDICAL BRANCH   (United States)

^b University of Texas Medical Branch School of Medicine   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALOSETRON; ANTIBIOTIC AGENT; BISMUTH SALICYLATE; DICYCLOVERINE; HYOSCYAMINE; LOPERAMIDE; METRONIDAZOLE; NEOMYCIN; OPIATE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAXIMIN; SEROTONIN UPTAKE INHIBITOR; SIMETHICONE; SPASMOLYTIC AGENT; TEGASEROD; TRICYCLIC ANTIDEPRESSANT AGENT;

ABDOMINAL DISCOMFORT; ABDOMINAL PAIN; ACUTE GASTROENTERITIS; BLOATING; CAMPYLOBACTER; CONSTIPATION; DEFECATION; DIARRHEA; DIET SUPPLEMENTATION; DISEASE DURATION; DYSENTERY; ENTEROPATHY; GASTROINTESTINAL SYMPTOM; HOST; HUMAN; INTESTINE MOTILITY; INTESTINE MUCOSA PERMEABILITY; INTESTINE PERFORATION; IRRITABLE COLON; ISCHEMIC COLITIS; LOOSE FECES; MENTAL DISEASE; PATHOGENESIS; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK; RISK FACTOR; SALMONELLA; SHIGELLA; TRAVELLER DIARRHEA; GASTROENTERITIS; PATHOLOGY; PATHOPHYSIOLOGY;

GASTROENTERITIS; HUMANS; IRRITABLE BOWEL SYNDROME; RISK FACTORS;

EID: 38849121514     PISSN: 10584838     EISSN: None     Source Type: Journal    
DOI: 10.1086/526774     Document Type: Review

References (56)

1. Neal KR, Barker L, Spiller RC. Prognosis in post-infective irritable bowel syndrome: a six year follow up study. Gut 2002; 51:410-3.
2. Spiller RC, Campbell E. Post-infectious irritable bowel syndrome. Curr Opin Gastroenterol 2006; 22:13-7.
3. Spiller RC, Jenkins D, Thornley JP, et al. Increased rectal mucosal enteroendocrine cells, T lymphocytes and increased gut permeability following acute Campylobacter enteritis and in post-dysenteric irritable bowel syndrome. Gut 2000; 47:804-11.
4. Gwee KA, Collins SM, Read NW. Increased rectal mucosal expression of interleukin 1b in recently acquired postinfectious irritable bowel syndrome. Gut 2003; 52:523-6.
5. Wang LH, Fang XC, Pan GZ. Bacillary dysentery as a causative factor of irritable bowel syndrome and its pathogenesis. Gut 2004; 53:1096-101.
6. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006; 130:1480-91.
7. Dunlop SP, Jenkins D, Spiller RC. Distinctive histological patterns of chronic inflammatory cells in rectal biopsies of patients with different clinical subtypes of IBS. Gastroenterology 2002; 122(Suppl 1):A60.
8. Neal KR, Hebden J, Spiller R. Prevalence of gastrointestinal symptoms six months after bacterial gastroenteritis and risk factors for development of the irritable bowel syndrome: postal survey of patients. BMJ 1997; 314:779-82.
9. Borgaonkar MR, Ford DC, Marshall JK, Churchill E, Collins SM. The incidence of irritable bowel syndrome among community subjects with previous acute enteric infection. Dig Dis Sci 2006; 51:1026-32.
10. Chaudhary NA, Truelove SC. The irritable colon syndrome: a study of the clinical features, predisposing causes, and prognosis in 130 cases. Q J Med 1962; 31:307-22.
11. Dunlop SP, Jenkins D, Neal KR, Spiller RC. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in post-infectious IBS. Gastroenterology 2003; 125:1651-9.
12. Gwee KA, Graham JC, McKendrick MW, et al. Psychometric scores and persistence of irritable bowel after infectious diarrhoea. Lancet 1996; 347: 150-3.
13. Gwee KA, Leong YL, Graham C, et al. The role of psychological and biological factors in postinfective gut dysfunction. Gut 1999; 44:400-6.
14. Ilnyckyj A, Balachandra B, Elliott L, et al. Post-traveler's diarrhea irritable bowel syndrome: a prospective study. Am J Gastroenterol 2003; 98:596-9.
15. Ji S, Park H, Lee D, Song YK, Choi JP, Lee SI. Post-infectious irritable bowel syndrome in patients with Shigella infection. J Gastroenterol Hepatol 2005; 20:381-6.
16. Marshall JK, Thabane M, Garg AX, Clark WF, Salvadori M, Collins SM. Incidence and epidemiology of irritable bowel syndrome after a large waterborne outbreak of bacterial dysentery. Gastroenterology 2006; 131:445-50.
17. McKendrick MW, Read NW. Irritable bowel syndrome-post Salmonella infection. J Infect 1994; 29:1-3.
18. Mearin F, Perez-Oliveras M, Perello A, et al. Dyspepsia and irritable bowel syndrome after a Salmonella gastroenteritis outbreak: one-year follow-up cohort study. Gastroenterology 2005; 129:98-104.
19. Okhuysen PC, Jiang SD, Carlin L, et al. Post-diarrhea chronic intestinal symptoms and irritable bowel syndrome in North American travelers to Mexico. Am J Gastroenterol 2004; 99:1774-8.
20. Parry SD, Stansfield R, Jelley D, et al. Does bacterial gastroenteritis predispose people to functional gastrointestinal disorders? A prospective, community-based, case-control study. Am J Gastroenterol 2003; 98:1970-5.
21. Rodríguez LA, Ruigómez A. Increased risk of irritable bowel syndrome after bacterial gastroenteritis: cohort study. BMJ 1999; 318:565-6.
22. Stermer E, Lubezky A, Potasman I, Paster E, Lavy A. Is traveler's diarrhea a significant risk factor for the development of irritable bowel syndrome? A prospective study. Clin Infect Dis 2006; 43:898-901.
23. Thornley JP, Jenkins D, Neal K, Wright T, Brough J, Spiller RC. Relationship of Campylobacter toxigenicity in vitro to the development of postinfectious irritable bowel syndrome. J Infect Dis 2001; 184:606-9.
24. Locke GR, Yawn BP, Woolan PC, Lydick E. The incidence of clinically diagnosed irritable bowel syndrome in the community. Gastroenterology 1999; 116:A76.
25. Halvorson HA, Schlett CD, Riddle MS. Post-infectious irritable bowel syndrome: a meta analysis. Am J Gastroenterol 2006; 101:1894-9.
26. Marshall JK, Thabane M, Borgaonkar MR, James C. Postinfectious irritable bowel syndrome after a food-borne outbreak of acute gastroenteritis attributed to a viral pathogen. Clin Gastroenterol Hepatol 2007; 5:457-60.
27. Parry SD, Barton JR, Welfare MR. Factors associated with the development of post-infectious functional gastrointestinal diseases: does smoking play a role? Eur J Gastroenterol Hepatol 2005; 17:1071-5.
28. Taylor DN, Houston R, Shlim DR, Bhaibulaya M, Ungar BL, Echeverria P. Etiology of diarrhea among travelers and foreign residents in Nepal. JAMA 1988; 260:1245-8.
29. Conner BA. Sequelae of traveler's diarrhea: focus on postinfectious irritable bowel syndrome. Clin Infect Dis 2005; 41(Suppl 8):S577-86.
30. Coates MD, Mahoney CR, Linden DR, et al. Molecular defects in mucosal serotonin content and decreased serotonin reuptake transporter in ulcerative colitis and irritable bowel syndrome. Gastroenterology 2004; 126:1657-64.
31. Dunlop SP, Coleman NS, Blackshaw E, et al. Abnormalities of 5-hydroxytryptamine metabolism in irritable bowel syndrome. Clin Gastroenterol Hepatol 2005; 3:349-57.
32. Marshall JK, Thabane M, Garg AX, et al. Intestinal permeability in patients with irritable bowel syndrome after a waterborne outbreak of acute gastroenteritis in Walkerton, Ontario. Aliment Pharmacol Ther 2004; 20:1317-22.
33. Niaz SK, Sandrasegaran K, Renny FH, Jones BJ. Postinfective diarrhoea and bile acid malabsorption. J R Coll Physicians Lond 1997; 31:53-6.
34. Sinha L, Liston R, Testa HJ, Moriarty KJ. Idiopathic bile acid malabsorption: qualitative and quantitative clinical features and response to cholestyramine. Aliment Pharmacol Ther 1998; 12:839-44.
35. Williams AJK, Merrick MV, Eastwood MA. Idiopathic bile acid malabsorption - a review of clinical presentation, diagnosis, and response to treatment. Gut 1991; 32:1004-6.
36. Szajewska H, Kantecki M, Albrecht P, Antoniewicz J. Carbohydrate intolerance after acute gastroenteritis - a disappearing problem in Polish children. Acta Paediatr 1997; 86:347-50.
37. Parry SD, Barton JR, Welfare MR. Is lactose intolerance implicated in the development of post-infectious irritable bowel syndrome or functional diarrhoea in previously asymptomatic people? Eur J Gastroenterol Hepatol 2002; 14:1225-30.
38. Peltola H, Gorbach SL. Travelers' diarrhea. In: Textbook of travel medicine and health. DuPont HL, Steffin R, eds. Zurich: BC Decker, 1997.
39. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003; 98:1578-83.
40. Hungin APS, Chang L, Locke GR, et al. Irritable bowel syndrome in the United States: prevalence, symptom patterns and impact. Aliment Pharmacol Ther 2005; 21:1365-75.
41. Vanner SJ, Depew WT, Paterson WG, et al. Predictive value of the Rome criteria for diagnosing the irritable bowel syndrome. Am J Gastroenterol 1999; 94:2912-7.
42. Clouse RE. Antidepressants for irritable bowel syndrome. Gut 2003; 52:598-9.
43. De Ponti F, Tonini M. Irritable bowel syndrome: new agents targeting serotonin receptor subtypes. Drugs 2001; 61:317-32.
44. Coffin B, Farmachidi JP, Rueegg P, et al. Tegaserod, a 5-HT4 receptor partial agonist, decreases sensitivity to rectal distention in healthy subjects. Aliment Pharmacol Ther 2003; 17:577-85.
45. Pimentel M, Chow EJ, Lin HC. Eradication of small intestinal bacterial overgrowth reduces symptoms of irritable bowel syndrome. Am J Gastroenterol 2000; 95:3503-6.
46. Pimentel M, Park S, Mirocha J, Kane SV, Kong Y. The effect of a nonabsorbed oral antibiotic (rifaximin) on the symptoms of the irritable bowel syndrome: a randomized trial. Ann Intern Med 2006; 145:557-63.
47. Kozicki M, Steffen R, Schar M. "Boil it, cook it, peel it, or forget it": does this rule prevent travellers' diarrhoea? Int J Epidemiol 1985; 14:169-72.
48. DuPont AW, DuPont HL. Travelers' diarrhea: modern concepts and new developments. Curr Treat Options Gastroenterol 2006; 9:13-21.
49. DuPont HL, Ericsson CD, Johnson PC, Bitsura JA, DuPont MW, de la Cabada FJ. Prevention of travelers' diarrhea by the tablet formulation of bismuth subsalicylate. JAMA 1987; 257:1347-50.
50. Johnson PC, Ericsson CD, Morgan DR, DuPont HL, Cabada FJ. Lack of emergence of resistant fecal flora during successful prophylaxis of travelers' diarrhea with norfloxacin. Antimicrob Agents Chemother 1986; 30:671-4.
51. Baker DE. Rifaximin: a nonabsorbed oral antibiotic. Rev Gastroenterol Disord 2005; 5:19-30.
52. DuPont HL, Jiang ZD, Okhuysen PC, et al. A randomized, double-blind, placebo-controlled trial of rifaximin to prevent travelers' diarrhea. Ann Intern Med 2005; 142:805-12.
53. Taylor DN, McKenzie R, Durbin A, et al. Rifaximin, a nonabsorbed oral antibiotic, prevents shigellosis after experimental challenge. Clin Infect Dis 2006; 42:1283-8.
54. Harvey RF, Mauad EC, Brown AM. Prognosis in the irritable bowel syndrome: a 5-year prospective study. Lancet 1987; 1:963-5.
55. McKendrick MW. Post Salmonella irritable bowel syndrome - 5-year review. J Infect 1996; 32:170-1.
56. Bennett EJ, Tennant CC, Piesse C, Badcock CA, Kellow JE. Level of chronic life stress predicts clinical outcome in irritable bowel syndrome. Gut 1998; 43:256-61.